Universe Pharmaceuticals vs Vertex Pharmaceuticals
UPC and VRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How UPC and VRTX compare
Vertex Pharmaceuticals grew revenue faster over the last twelve months (10.2% versus −22.4% for Universe Pharmaceuticals).
Vertex Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.0% compared with −20.6% at Universe Pharmaceuticals.
Vertex Pharmaceuticals scores higher on the StockData Score (15 against 5 for Universe Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | UPC | VRTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $137B |
| Share price | $1.51 | $538.60 |
| Change, 1 year | −59.0% | 24.0% |
| Change, 5 years | −100.0% | 195% |
| Beta (5Y) | 1.06 | 0.52 |
| Employees | 225 | 600K |
| StockData Score | ||
| Total score | 5 | 15 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 6 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 31.4× |
| P/S | – | 10.8× |
| P/B | – | 6.7× |
| EV/EBITDA | – | 25.7× |
| P/FCF | – | 36.0× |
| PEG | – | 5.12 |
| FCF yield | – | 2.8% |
| Fair value | – | $426.36 |
| Margin of safety | – | −26.3% |
| Growth | ||
| Revenue growth (TTM) | −22.4% | 10.2% (better) |
| Revenue growth, 5Y average | 257% (better) | 14.1% |
| Net income growth (TTM) | – | 21.1% |
| EPS growth (TTM) | – | 22.4% |
| EPS growth, 5Y average | – | 8.3% |
| Profitability | ||
| Gross margin | 35.3% | 86.0% (better) |
| Operating margin | −16.3% | 38.0% (better) |
| Net margin | −20.6% | 35.0% (better) |
| FCF margin | −29.8% | 30.2% (better) |
| Return on equity | −7261% | 23.5% (better) |
| Return on invested capital | −78.0% | 34.4% (better) |
| Financial health | ||
| Debt / equity | 0.13 (better) | 0.00 |
| Interest coverage | −10.1× | – |
| Current ratio | 4.05 (better) | 3.19 |
| Altman Z-score | – | 13.63 |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 1.5% |
| Shareholder yield | – | 1.5% |
| Ownership | ||
| Held by institutions | 6.6% | 95.6% |
| Held by insiders | – | 0.22% |
| Insider net buying, 12 months | – | −$131M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 1.9% |
Go deeper
- UPC stock overview
- UPC income statement
- UPC valuation and score
- VRTX stock overview
- VRTX income statement
- VRTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.